SGLT2 inhibitor for anemia in chronic kidney disease
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study tests whether a type of diabetes drug, called an SGLT2 inhibitor, can help improve anemia (low red blood cell count) in people with chronic kidney disease (CKD) but not yet on dialysis. If you have mild-to-moderate anemia and stable kidney function, this drug might help boost your blood counts and improve your energy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have chronic kidney disease (CKD) stages 1 through 4, meaning you are not on dialysis yet.
- Your hemoglobin (a red blood cell measure) levels are between 8.5 and 12.9 g/dL.
- Your anemia treatment has been stable for at least 8 weeks without dose changes.
- You have not had dialysis, a blood transfusion, major cancer, or an active infection recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
This trial looks at whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help protect the kidneys and heart in people with chronic kidney disease or type 2 diabetes. If you have either condition, you might be able to join.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
This study looks at using a urine test to help diagnose and monitor chronic kidney disease (CKD), a condition where your kidneys slowly lose function over time. The study also checks how well a type of medicine called SGLT2 inhibitors (often used for diabetes) actually works in real life for people with CKD. If you have CKD, this research could help improve monitoring and treatment decisions.
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
Hear when a new Anemia in CKD Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.